Tirzepatide Might possibly perchance simply Back Treat Sleep Apnea in People With Obesity

ORLANDO — Tirzepatide (Zepbound) improved indicators of moderate-to-severe obstructive sleep apnea (OSA) in of us with weight problems, no matter particular airway rigidity (PAP) teach, the piece III SURMOUNT OSA trials stumbled on.

For these no longer on PAP (trial 1), tirzepatide ended in a mean trade at week 52 within the apnea-hypopnea index (AHI) of -25.3 occasions per hour, as when in contrast with -5.3 occasions per hour for placebo (estimated therapy difference of -20.0 occasions, 95% CI -25.8 to -14.2, P<0.001).

Mean trade in AHI at week 52 among the PAP customers (trial 2) turned into once -29.3 occasions per hour with tirzepatide when in contrast with -5.5 occasions with placebo (estimated therapy difference -23.8 occasions, 95% CI -29.6 to -17.9, P<0.001), reported Atul Malhotra, MD, of the University of California San Diego, at the annual American Diabetes Affiliation Scientific Sessions.

“We bring together now a seemingly new therapy for obstructive sleep apnea in an effort to add to existing therapies,” stated Malhotra.

The findings don’t basically mean patients can ditch their proper particular airway rigidity (CPAP) machines, Malhotra stated. “I am a expansive believer that CPAP … is first-line therapy for obstructive sleep apnea, nonetheless that does not tackle the weight problems-connected cardiometabolic complications,” he stated. “My perception might be treating each and each weight problems and sleep apnea is dawdle.”

The more weight you lose, the larger, Malhotra instantaneous MedPage This day. “Some of us pronounce for each and each pound you lose, the much less sleep apnea you bring together got got. Varied of us deem there is a threshold the build you bring together under a screech weight and sleep apnea goes away. Scientific skills suggests it is moderately variable.”

Outcomes of the pains had been simultaneously printed within the Unique England Journal of Medication.

Tirzepatide confirmed most necessary improvements in all prespecified key secondary endpoints in each and each trials. Systolic blood rigidity improved with tirzepatide from baseline, with reductions of 9.5 mm Hg in trial 1, and 7.6 mm Hg in trial 2, which Malhotra stated turned into once “possibly doubtlessly the most putting result.”

“The event in systolic blood rigidity that turned into once considered with tirzepatide turned into once seriously increased than effects considered with CPAP therapy alone and point to that tirzepatide might additionally very smartly be a impartial appropriate wanting choice for these patients who discover to chop their cardiovascular chance,” seen Sanjay Patel, MD, of the University of Pittsburgh, in an accompanying editorial.

The benefits of tirzepatide for weight reduction also might be expanded to patients who might additionally income from second-line therapies for OSA cherish mandibular-development gadgets or hypoglossal-nerve stimulation, Patel suggested.

At the originate authorized for form 2 diabetes in 2022 (under the emblem name Mounjaro), tirzepatide, a aggregate glucagon-cherish peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, received approval for adult power weight administration unhurried final year.

In SURMOUNT OSA, 234 and 235 contributors had been divided into trials 1 and a pair of. Trial 1 included contributors who had been unable or unwilling to make teach of PAP therapy, while trial 2 included contributors who had been the teach of PAP therapy for no longer no longer as much as 3 months and deliberate to continue it exact throughout the trial.

All contributors had weight problems (BMI of ≥30 or ≥27 in Japan) and a diagnosis of moderate-to-severe obstructive sleep apnea (AHI ≥15 occasions per hour). Diabetes, a diagnosis of central or mixed sleep apnea, and predominant craniofacial abnormalities had been some exclusion standards. Male enrollment turned into once capped at 70%.

At baseline, the mean AHI turned into once 51.5 occasions per hour in trial 1 and 49.5 occasions per hour in trial 2. Sensible BMI turned into once 39.1 and 38.7, respectively.

The starting tirzepatide dose turned into once 2.5 mg once weekly, which turned into once increased by 2.5 mg each and each 4 weeks except contributors reached the utmost tolerated dose of 10 mg or 15 mg in week 20. All contributors bought traditional contrivance of life counseling classes relating to vitamin; they had a 500 kcal/day deficit and no longer no longer as much as 150 minutes/week of bodily process.

Body weight reductions had been 17.7% in trial 1 and 19.6% in trial 2 — no longer as high as they had been within the real SURMOUNT-1 trial underpinning tirzepatide’s approval for power weight administration. This turned into once “seemingly connected to length of therapy and gender balances within the studies,” Malhotra stated.

The most fashioned facet effects in SURMOUNT OSA had been gastrointestinal, which were generally gentle to moderate. Most frequent had been diarrhea, nausea, vomiting, and constipation.

Two circumstances of acute pancreatitis took place within the trial 2 tirzepatide community. 5 circumstances of severe or severe depressive dysfunction or suicidal ideation or habits occasions took place across each and each trials (two with tirzepatide and three with placebo).

Though discontinuation turned into once low (3-4%), Patel pointed out that accurate-world files indicates around half of of patients who beginning therapy with a GLP-1 receptor agonist for weight problems pause therapy within 12 months. Adherence to CPAP therapy also tends to be suboptimal, he important.

“It is seemingly that any incorporation of tirzepatide into therapy pathways for obstructive sleep apnea won’t diminish the importance of prolonged-term systems to optimize adherence to therapy,” he stated.

Drugmaker Eli Lilly stated it submitted tirzepatide for the therapy of moderate-to-severe OSA in patients with weight problems to the FDA. The firm expects regulatory action as early as the cease of the year.

  • author['full_name']

    Kristen Monaco is a senior workers writer, specializing in endocrinology, psychiatry, and nephrology news. Essentially based entirely out of the Unique York City region of job, she’s labored at the firm since 2015.


The trial turned into once funded by Eli Lilly.

Malhotra reported relationships with Eli Lilly, Healcisio, LivaNova USA, Daybreak, University of California San Diego, and ZOLL Scientific Company. Quite loads of co-authors reported disclosures, including relationships with Eli Lilly.

Patel reported relationships with Apnimed, Bayer HealthCare Pharmaceuticals, Breathe PA, Lilly, NovaResp Applied sciences, Philips, and Powell Mansfield.

Major Provide

Unique England Journal of Medication

Provide Reference: Malhotra A, et al “Tirzepatide for the therapy of obstructive sleep apnea and weight problems” N Engl J Med 2024; DOI: 10.1056/NEJMoa2404881.

Secondary Provide

Unique England Journal of Medication

Provide Reference: Patel SR, et al “Entering a brand new era in sleep-apnea therapy” N Engl J Med 2024; DOI: 10.1056/NEJMe2407117.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button